According to results from an ongoing phase I trial, the novel immune checkpoint inhibitor COM701, which targets PVRIG, has shown early signs of efficacy, on its own and combined with nivolumab, in patients with a variety of advanced solid tumors.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.